Literature DB >> 16059637

Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.

Jay J Cao1, Thomas J Wronski, Urszula Iwaniec, Laura Phleger, Pam Kurimoto, Benjamin Boudignon, Bernard P Halloran.   

Abstract

UNLABELLED: Stromal/osteoblastic cell expression of RANKL and M-CSF regulates osteoclastogenesis. We show that aging is accompanied by increased RANKL and M-CSF expression, increased stromal/osteoblastic cell-induced osteoclastogenesis, and expansion of the osteoclast precursor pool. These changes correlate with age-related alterations in the relationship between osteoblasts and osteoclasts in cancellous bone.
INTRODUCTION: Bone mass is maintained through a balance between osteoblast and osteoclast activity. Osteoblasts regulate the number and activity of osteoclasts through expression of RANKL, osteoprotegerin (OPG), and macrophage-colony stimulation factor (M-CSF). To determine whether age-related changes in stromal/osteoblastic cell expression of RANKL, OPG, and M-CSF are associated with stimulation of osteoclastogenesis and whether the osteoclast precursor pool changes with age, we studied cultures of stromal/osteoblastic cells and osteoclast precursor cells from animals of different ages and examined how aging influences bone cell populations in vivo.
MATERIALS AND METHODS: Osteoclast precursors from male C57BL/6 mice of 6 weeks (young), 6 months (adult), and 24 months (old) of age were either co-cultured with stromal/osteoblastic cells from young, adult, or old mice or treated with M-CSF, RANKL, and/or OPG. Osteoclast precursor pool size was determined by fluorescence-activated cell sorting (FACS), and osteoclast formation was assessed by measuring the number of multinucleated TRACP(+) cells and pit formation. The levels of mRNA for RANKL, M-CSF, and OPG were determined by quantitative RT-PCR, and transcription was measured by PCR-based run-on assays. Osteoblast and osteoclast numbers in bone were measured by histomorphometry.
RESULTS: Osteoclast formation increased dramatically when stromal/osteoblastic cells from old compared with young donors were used to induce osteoclastogenesis. Regardless of the origin of the stromal/osteoblastic cells, the number of osteoclasts formed from the nonadherent population of cells increased with increasing age. Stromal/osteoblastic cell expression of RANKL and M-CSF increased, whereas OPG decreased with aging. Exogenously administered RANKL and M-CSF increased, dose-dependently, osteoclast formation from all donors, but the response was greater in cells from old donors. Osteoclast formation in vitro positively, and the ratio of osteoblasts to osteoclasts in vivo negatively, correlated with the ratio of RANKL to OPG expression in stromal/osteoblastic cells for all ages. The effects of RANKL-induced osteoclastogenesis in vitro were blocked by OPG, suggesting a causal relationship between RANKL expression and osteoclast-inducing potential. The osteoclast precursor pool and expression of RANK and c-fms increased with age.
CONCLUSIONS: Our results show that aging significantly increases stromal/osteoblastic cell-induced osteoclastogenesis, promotes expansion of the osteoclast precursor pool and alters the relationship between osteoblasts and osteoclasts in cancellous bone.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16059637     DOI: 10.1359/JBMR.050503

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  62 in total

Review 1.  Aging and bone.

Authors:  A L Boskey; R Coleman
Journal:  J Dent Res       Date:  2010-10-05       Impact factor: 6.116

Review 2.  Innate immunity and aging.

Authors:  Christian R Gomez; Vanessa Nomellini; Douglas E Faunce; Elizabeth J Kovacs
Journal:  Exp Gerontol       Date:  2008-06-11       Impact factor: 4.032

Review 3.  Selective targeting of RANK signaling pathways as new therapeutic strategies for osteoporosis.

Authors:  Joel Jules; Jason W Ashley; Xu Feng
Journal:  Expert Opin Ther Targets       Date:  2010-09       Impact factor: 6.902

Review 4.  Childhood obesity, bone development, and cardiometabolic risk factors.

Authors:  Norman K Pollock
Journal:  Mol Cell Endocrinol       Date:  2015-03-27       Impact factor: 4.102

5.  Simulated spaceflight produces a rapid and sustained loss of osteoprogenitors and an acute but transitory rise of osteoclast precursors in two genetic strains of mice.

Authors:  Mohammad Shahnazari; Pam Kurimoto; Benjamin M Boudignon; Benjamin E Orwoll; Daniel D Bikle; Bernard P Halloran
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-10-09       Impact factor: 4.310

6.  NF-κB RelB negatively regulates osteoblast differentiation and bone formation.

Authors:  Zhenqiang Yao; Yanyun Li; Xiaoxiang Yin; Yufeng Dong; Lianping Xing; Brendan F Boyce
Journal:  J Bone Miner Res       Date:  2014-04       Impact factor: 6.741

Review 7.  Bone mechanotransduction may require augmentation in order to strengthen the senescent skeleton.

Authors:  Sundar Srinivasan; Ted S Gross; Steven D Bain
Journal:  Ageing Res Rev       Date:  2012-01-05       Impact factor: 10.895

8.  Bisphosphonates inhibit surface-mediated osteogenesis.

Authors:  Ethan M Lotz; Christoph H Lohmann; Barbara D Boyan; Zvi Schwartz
Journal:  J Biomed Mater Res A       Date:  2020-04-21       Impact factor: 4.396

9.  Passage-affected competitive regulation of osteoprotegerin synthesis and the receptor activator of nuclear factor-kappaB ligand mRNA expression in normal human osteoblasts stimulated by the application of cyclic tensile strain.

Authors:  Akinori Kusumi; Tomomi Kusumi; Jun Miura; Tomonori Tateishi
Journal:  J Bone Miner Metab       Date:  2009-05-19       Impact factor: 2.626

10.  Intrinsic Sex-Linked Variations in Osteogenic and Adipogenic Differentiation Potential of Bone Marrow Multipotent Stromal Cells.

Authors:  Beth Bragdon; Robert Burns; Amelia H Baker; Anna C Belkina; Elise F Morgan; Gerald V Denis; Louis C Gerstenfeld; Jennifer J Schlezinger
Journal:  J Cell Physiol       Date:  2015-02       Impact factor: 6.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.